Melissa Lumish, MD
-
Specialty: Hematology and Oncology
View Expertise -
Primary Location: 11100 Euclid Ave (0 mi.)
Other Locations - Languages Spoken: English
Office Locations
UH Seidman Cancer Center (0 mi.)
11100 Euclid Ave
1st Floor
Cleveland, OH 44106
216-844-3951
UH Seidman Minoff Health Center (7 mi.)
3909 Orange Pl
Ste 1100
Beachwood, OH 44122
216-896-1750
UH Seidman Minoff Health Center (7 mi.)
3909 Orange Pl
Ste 4600
Beachwood, OH 44122
216-844-3951
Biography: Melissa Lumish, MD
Expertise
Titles
- Clinical Assistant Professor, CWRU School of Medicine
Certifications & Memberships
- Medical Oncology - American Board of Internal Medicine
- Internal Medicine - American Board of Internal Medicine
Education
Fellowship | Hematology/Oncology
Hematology/Oncology - Memorial Sloan-Kettering Cancer Center (2019 - 2022)
Residency | Internal Medicine
Internal Medicine - Massachusetts General Hospital (2016 - 2019)
Medical Education
New York University School Of Medicine And Langone Medical Center (2016)
Undergraduate
Cornell University (2010)
About
Melissa Lumish, MD, is a medical oncologist at University Hospitals Seidman Cancer Center with expertise in gastrointestinal cancers. Her specific areas of interest are early onset gastrointestinal cancers (young adults under the age of 50), the use of immunotherapy and the role of the microbiome in cancer growth and treatment.
Before she was recruited to join University Hospitals, Dr. Lumish was a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City. Dr. Lumish earned her undergraduate degree from Cornell University and her medical degree from New York University School of Medicine. She completed an internal medicine residency at Massachusetts General Hospital/Harvard Medical School in Boston, Massachusetts and a fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center.
Dr. Lumish’s research has been published in the New England Journal of Medicine, Journal of Clinical Oncology, JAMA Oncology, Journal for ImmunoTherapy of Cancer, American Journal of Surgery, Journal of Surgical Oncology and Scientific Reports. She was one of the researchers involved in a small but groundbreaking clinical trial published in the New England Journal of Medicine which showed that patients with mismatch repair deficient locally advanced rectal cancer can achieve a complete clinical response with 6 months of treatment with an immune checkpoint inhibitor (dostarlimab) without radiation, surgery or chemotherapy.
Among other honors and awards, Dr. Lumish is the recipient of the American Association for Cancer Research 2021 Doreen J. Putrah Cancer Research Foundation Scholar-in-Training Award, 2021; Annual Meeting Merit Award, American Society of Clinical Oncology, 2021; Donald L. Morton Award, 9th Annual, Journal of Surgical Oncology, 2022; and Conquer Cancer Young Investigator Award, American Society of Clinical Oncology, Conquer Cancer, 2022.
Featured Videos
Watch to find out more about this University Hospitals provider.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Melissa Lumish did not disclose any Outside Relationships with Industry.